Shopping Cart
Remove All
Your shopping cart is currently empty
Sotuletinib hydrochloride (BLZ945 HCl) is a selective, brain-penetrant CSF-1R (c-Fms) inhibitor (IC50=1 nM), exhibiting 1000-fold greater selectivity than other receptor tyrosine kinase homologues. It elevates liver enzymes and induces Kupffer cell depletion, making it suitable for studying amyotrophic lateral sclerosis (ALS) and metastatic triple-negative breast cancer (TNBC).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $32 | - | In Stock | |
| 5 mg | $73 | - | In Stock | |
| 10 mg | $113 | - | In Stock | |
| 25 mg | $172 | - | In Stock | |
| 50 mg | $228 | - | In Stock | |
| 100 mg | $396 | - | In Stock | |
| 200 mg | $578 | - | In Stock |
| Description | Sotuletinib hydrochloride (BLZ945 HCl) is a selective, brain-penetrant CSF-1R (c-Fms) inhibitor (IC50=1 nM), exhibiting 1000-fold greater selectivity than other receptor tyrosine kinase homologues. It elevates liver enzymes and induces Kupffer cell depletion, making it suitable for studying amyotrophic lateral sclerosis (ALS) and metastatic triple-negative breast cancer (TNBC). |
| Targets&IC50 | CSF1R (FMS):1 nM |
| In vitro | Methods: Bone marrow-derived macrophages (BMDMs) were treated with Sotuletinib hydrochloride (67nM-6700nM), and cell proliferation was assessed via MTT assay. Results: Sotuletinib hydrochloride significantly inhibited CSF-1-dependent proliferation and CSF-1R phosphorylation in BMDMs.[1] |
| In vivo | Methods: Sotuletinib hydrochloride (200 mg/kg, once daily) was administered to MMTV-PyMT mice via oral gavage to assess the effects of Sotuletinib hydrochloride on tumor growth, TAMs, and CD8+ T cells. Results: Sotuletinib hydrochloride treatment significantly decreased TAMs and tumor volume while enhancing the infiltration of CD8+ T cells.[2] |
| Molecular Weight | 434.94 |
| Formula | C20H23ClN4O3S |
| Cas No. | 2222138-31-8 |
| Smiles | N(C=1SC=2C(N1)=CC=C(OC=3C=C(C(NC)=O)N=CC3)C2)[C@H]4[C@H](O)CCCC4.Cl |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80.00 mg/mL (183.93 mM), Sonication is recommended. H2O: 80.00 mg/mL (183.93 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.59 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/H2O
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.